ISSUANCE OF EQUITY SHARES BY WAY OF PREFERENTIAL ISSUE ON PRIVATE PLACEMENT BASIS FOR CONSIDERATION OTHER THAN CASH (SHARE SWAP)
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.9 pts more than Nifty Microcap 250 and 1.6 pts more than its Computers - Software & Consulting peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board of Directors approved a preferential issue of 1,61,82,800 equity shares at Rs. 48.20 per share (face value Rs. 10 + premium Rs. 38.20) via a share swap to acquire 100% of iSERA Biological Limited from its existing shareholders for a total consideration of Rs. 78 crore. Both companies were independently valued — iSERA Lifesciences at Rs. 48.15 per share (floor price) and iSERA Biological at Rs. 48.20 per share — resulting in a 1:1 swap ratio. The deal is classified as a related party transaction (promoter group holds stakes in target) and is subject to shareholder approval via postal ballot and BSE in-principle approval. iSERA Biological had turnover of Rs. 183.6 crore in FY 2024-25 with EBITDA of Rs. 76.7 crore. The company also increased authorised capital from Rs. 11 crore to Rs. 25 crore and enhanced Section 186 investment limits to Rs. 1,000 crore. 196 allottees include existing promoters, family members, and non-promoter investors including NAV Capital Emerging Star Fund (10 lakh shares) and M7 Global Fund (4.24 lakh shares).
Existing shareholders face dilution of approximately 39.7% from this large share issuance. Post-issue, promoter group voting power will increase materially, while iSERA Biological becomes a wholly-owned subsidiary, consolidating financials. No cash outflow for the company; valuation appears fair at near-par rates.